Group I p21-activated kinases in leukemia cell adhesion to fibronectin

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• P21-activated kinases (PAK) are crucial regulators of the actin cytoskeleton, influencing cell shape, migration, and survival.
• PAK dysregulation is implicated in various cancers, including leukemia, highlighting their potential as therapeutic targets.

Purpose of the Study:

• To investigate the role of PAK1 and PAK2 in leukemia cell adhesion and viability.
• To evaluate the effects of specific PAK inhibitors (IPA-3 and FRAX597) on leukemia cell behavior.

Main Methods:

• Quantitative analysis of PAK1 and PAK2 expression at protein and mRNA levels in leukemia cell lines and primary cells.
• Functional assays assessing cell adhesivity, surface integrin density, and cell viability upon treatment with PAK inhibitors.
• Immunofluorescence microscopy to determine the subcellular localization of PAK isoforms.

Main Results:

• PAK2 was the predominant isoform in leukemia cell lines, while primary cells also expressed PAK1 isoforms (PAK1-full and PAK1Δ15).
• PAK1Δ15 and PAK2 expression levels correlated with the surface density of integrins β1 and αVβ3.
• PAK1-full localized to membrane protrusions, whereas PAK2 did not.
• IPA-3 induced cell contraction in specific leukemia cells, while FRAX597 increased cell-surface contact area in all tested leukemia cells.
• Both inhibitors destabilized cell attachment and promoted leukemia cell death.

Conclusions:

• PAK1 and PAK2 play significant roles in regulating leukemia cell adhesion and survival through interactions with integrins.
• PAK inhibitors demonstrate potential as anti-leukemia agents by disrupting cell attachment and inducing apoptosis.
• Targeting PAK signaling pathways represents a promising therapeutic strategy for leukemia treatment.